ArticleEndocrine2026
MiR-342-3p is a novel biomarker for the diagnosis and regulates tumorigenesis in thyroid papillary cancer through FOXQ1.
Article in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe downregulated level of miR-342-3p has been reported in various kinds of human malignancies. It remains unclear the biological function of miR-342-3p in pappillary thyroid carcinoma (PTC). In this study, we assess the expression pattern of miR-342-3p and determine its potential role as biomarker in PTC, furthermore investigate its biological role during tumorigenesis.
methodsThe quantitative real-time PCR (qRT-PCR) was performed to measure the expression of miR-342-3p in 36 PTC tissue and in two human PTC cell lines (TPC-1 and B-CPAP). miR-342-3p mimic/inhibitor and si-FOXQ1 were transfected into TPC-1 and B-CPAP cells. The effects of miR-342-3p on the proliferation, invasion and migration of PTC cells were evaluated by Cell Counting Kit 8 (CCK-8), transwell and scratch healing assays. Flow cytometry analysis was performed to examine cell cycle and apoptosis. Expression levels of FOXQ1 in cells were assessed using Western blotting. The relationship between miR-342-3p and FOXQ1 was explored by Dual-luciferase reporter assay.
resultsOur findings revealed that miR-342-3p was low expressed in PTC tissue specimens and cell lines. Decreased expression of miR-342-3p was related to the AJCC stage. Meanwhile, the area under the receiver operating characteristic (ROC) was 0.714 (95%CI = 0.576–0.853), with a sensitivity of 63.9%, specificity of 69.4%, Youden index of 0.333 at cut-off value of 0.78. Ectopic upregulation of miR-342-3p and knockdown of FOXQ1 determined a reduction of PTC cell proliferation, migration, invasion, induced apoptosis in TPC-1 cells. Silencing miR-342-3p led to the opposite results. Additionally, FOXQ1 was found to be a target of miR-342-3p and this correlation was confirmed by dual-luciferase assay and Western blot.
conclusionsIn the present study, we demonstrate that miR-342-3p may be a novel potential marker for the diagnosis in PTC. Our findings suggest that miR-342-3p acts as tumor suppressor that plays an important role in PTC progression through targeting FOXQ1 signaling pathway, which indicates that miR-342-3p/FOXQ1 could be a therapeutic target for PTC.
Indexed as
Identifiers
41920246What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.